DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Dichotic Listening as a Predictor of Medication Response in Depression

Information source: New York State Psychiatric Institute
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Major Depression; Dysthymia; Depressive Disorder NOS

Intervention: Fluoxetine (Drug); Imipramine (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: New York State Psychiatric Institute

Official(s) and/or principal investigator(s):
Jonathan W. Stewart, MD., Principal Investigator, Affiliation: New York State Psychiatric Institute - Columbia University Department of Psychiatry


Depressed patients will have hearing tests and then be treated with up to three treatments (i. e., Fluoxetine, Imipramine and Placebo) until remitted, to see whether test results predict specific outcomes.

Clinical Details

Official title: Dichotic Listening as a Predictor of Placebo and Medication Response in Depression

Study design: Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Hamilton Depression Scale (HAM-D)

Secondary outcome:

Clinical Global Impression Scale (CGI)

Atypical Depression Diagnostic Scale (ADDS)

Deragotis Sexual Performance Scale

Snaith-Hamilton Pleasure Scale

Spielberger State/Trait Anxiety Scale

Detailed description: Preliminary data suggest that depressed patients with increased left hemispheric laterality of perceptual processing are unlikely to improve during six weeks' treatment with placebo, while being very responsive to either imipramine or fluoxetine. Depressed patients who do not show evidence of poor right hemispheric functioning respond significantly more often to placebo than those with poor right hemispheric functioning, and do not show an advantage of drug over placebo. 100 depressed patients will be tested with verbal and nonverbal dichotic tests, and then treated sequentially with Placebo, Fluoxetine and Imipramine until remitted. Preferential hemisphere for auditory processing will be correlated with treatment outcome.


Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.


Inclusion Criteria:

- Ages between 18-65

- Meets DSM-IV criteria for current Major Depression, Dysthymia or Depression NOS

Exclusion Criteria:

- Known hearing impairment

- Active suicidal ideation (history of suicide attempts will be evaluated on a case by

case basis)

- HAMD > 20

- Current (past six months) alcohol and/or drug abuse or dependence

- Medical condition likely to require intervention contraindicated with study

medication (e. g., known arrhythmia likely to be exacerbated by Imipramine)

- Bipolar I

- Psychosis

- If currently taking antidepressants or mood stabilizers, cannot be off psychotropic

medication for 7 weeks (10 weeks for Prozac) or felt to require other psychiatric medication (other than occasional sleep or Anxiety medication)

- Premenopausal women not using known effective birth control

- Not currently depressed (whether considered due to current treatment or not)

- Nonresponse to adequate trial of both study medications (i. e., > 4weeks on >

escitalopram 30 mg/d, and imipramine 200 mg/d); patients having an inadequate response to one study medication could be enrolled and receive the other; patients having responded to an adequate trial of either study medication would be offered a retrial; also excluded will be subjects having non responded to an adequate trial with citalopram (i. e., > 4 weeks on > citalopram 60 mg/d)

- Left-handed

Locations and Contacts

Depression Evaluation Service, New York State Psychiatric Institute, New York, New York 10032, United States
Additional Information

Depression Evaluation Service - official website

New York State Psychiatric Institute - official website

Related publications:

Bruder GE, Otto MW, McGrath PJ, Stewart JW, Fava M, Rosenbaum JF, Quitkin FM. Dichotic listening before and after fluoxetine treatment for major depression: relations of laterality to therapeutic response. Neuropsychopharmacology. 1996 Aug;15(2):171-9.

Bruder GE, Stewart JW, Tenke CE, McGrath PJ, Leite P, Bhattacharya N, Quitkin FM. Electroencephalographic and perceptual asymmetry differences between responders and nonresponders to an SSRI antidepressant. Biol Psychiatry. 2001 Mar 1;49(5):416-25.

Bruder GE, Stewart JW, McGrath PJ, Deliyannides D, Quitkin FM. Dichotic listening tests of functional brain asymmetry predict response to fluoxetine in depressed women and men. Neuropsychopharmacology. 2004 Sep;29(9):1752-61.

Stewart JW, Quitkin FM, McGrath PJ, Bruder GE. Do tricyclic responders have different brain laterality? J Abnorm Psychol. 1999 Nov;108(4):707-10.

Bruder GE, Stewart JW, Voglmaier MM, Harrison WM, McGrath P, Tricamo E, Quitkin FM. Cerebral laterality and depression: relations of perceptual asymmetry to outcome of treatment with tricyclic antidepressants. Neuropsychopharmacology. 1990 Feb;3(1):1-10.

Starting date: April 1994
Last updated: April 26, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017